Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma
暂无分享,去创建一个
L. Wood | K. Kinzler | B. Vogelstein | Siân Jones | R. Karchin | N. Papadopoulos | C. Tokheim | L. Marchionni | E. Fertig | J. Bishop | N. Niknafs | M. Sausen | N. Agrawal | S. Wheelan | M. Considine | P. Ha | C. Fakhry | E. Rettig | C. Talbot | Shizhang Ling | Collin J Tokheim
[1] Huining Kang,et al. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. , 2016, Cancer discovery.
[2] P. A. Futreal,et al. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations , 2015, Clinical Cancer Research.
[3] B. Carneiro,et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling , 2015, Oncotarget.
[4] Yi Zheng,et al. Approaches of targeting Rho GTPases in cancer drug discovery , 2015, Expert opinion on drug discovery.
[5] R. Karchin,et al. Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features , 2015, Cancer Prevention Research.
[6] Steven J. M. Jones,et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.
[7] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[8] Min Zhang,et al. A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets , 2014, Oncotarget.
[9] R. Carrau,et al. Clinicopathologic predictors of recurrence and overall survival in adenoid cystic carcinoma of the head and neck: A single institutional experience at a tertiary care center , 2014, Head & neck.
[10] L. Wood,et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors , 2014, Nature Genetics.
[11] A. Bass,et al. Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor suppressor activities , 2014, Oncogene.
[12] Jane Y. Wu,et al. Axon guidance factor SLIT2 inhibits neural invasion and metastasis in pancreatic cancer. , 2014, Cancer research.
[13] Charity W. Law,et al. voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.
[14] P. Stephens,et al. Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies , 2014, The American journal of surgical pathology.
[15] K. Kinzler,et al. Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing , 2013, Science Translational Medicine.
[16] M. Stratton,et al. Whole exome sequencing of adenoid cystic carcinoma. , 2013, The Journal of clinical investigation.
[17] Benjamin J. Raphael,et al. The Mutational Landscape of Adenoid Cystic Carcinoma , 2013, Nature Genetics.
[18] Liliana Goumnerova,et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1 , 2013, Proceedings of the National Academy of Sciences.
[19] Ning Leng,et al. EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments , 2013, Bioinform..
[20] Giovanni Parmigiani,et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.
[21] R. Ferris,et al. Molecular biology of adenoid cystic carcinoma , 2012, Head & neck.
[22] P. A. Futreal,et al. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma , 2012, Genes, chromosomes & cancer.
[23] J. Aster,et al. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Wonshik Han,et al. NFIB is a potential target for estrogen receptor‐negative breast cancers , 2011, Molecular oncology.
[25] G. Hostetter,et al. Perineural invasion and associated pain in pancreatic cancer , 2011, Nature Reviews Cancer.
[26] C. Moskaluk,et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms , 2011, Modern Pathology.
[27] R. Gibbs,et al. Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.
[28] S. Salzberg,et al. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts , 2011, Genome Biology.
[29] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[30] Levi Garraway,et al. Nuclear factor I/B is an oncogene in small cell lung cancer. , 2011, Genes & development.
[31] A. Capobianco,et al. Notch signalling in solid tumours: a little bit of everything but not all the time , 2011, Nature Reviews Cancer.
[32] R. West,et al. MYB Expression and Translocation in Adenoid Cystic Carcinomas and Other Salivary Gland Tumors With Clinicopathologic Correlation , 2011, The American journal of surgical pathology.
[33] Paola Chiarugi,et al. Rac and Rho GTPases in cancer cell motility control , 2010, Cell Communication and Signaling.
[34] R. Weber,et al. Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance , 2010, Clinical Cancer Research.
[35] M. Wjst,et al. Copy number variation and association over T-cell receptor genes—influence of DNA source , 2010, Immunogenetics.
[36] H. Horlings,et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.
[37] Hiromi Nakamura,et al. ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis , 2009, The EMBO journal.
[38] A. Italiano,et al. NFIB rearrangement in superficial, retroperitoneal, and colonic lipomas with aberrations involving chromosome band 9p22 , 2008, Genes, chromosomes & cancer.
[39] E. Sahai,et al. Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement , 2008, Cell.
[40] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[41] Robert G. Ramsay,et al. MYB function in normal and cancer cells , 2008, Nature Reviews Cancer.
[42] A. Ridley,et al. Rho GTPases in cancer cell biology , 2008, FEBS letters.
[43] J. Lacal,et al. Rho GTPase expression in tumourigenesis: Evidence for a significant link , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.
[44] Andrew I Su,et al. Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. , 2002, The American journal of pathology.
[45] J. Camonis,et al. Mutation status of genes encoding RhoA, Rac1, and Cdc42 GTPases in a panel of invasive human colorectal and breast tumors , 2001, Journal of Cancer Research and Clinical Oncology.
[46] H. Goepfert,et al. Adenoid cystic carcinoma of the head and neck: Predictors of morbidity and mortality , 1999 .
[47] E. Schoenmakers,et al. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas , 1998, Oncogene.
[48] M. Jaggi,et al. Slit/Robo pathway: a promising therapeutic target for cancer. , 2015, Drug discovery today.